We are monitoring the impact of COVID-19 & Recession alarm on Europe Generic Drugs Market Get in touch with us for detailed analysis Know More
Share on

Europe Generic Drugs Market Research Report - Segmented By Type, Application, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2092
Pages: 145

Europe Generic Drugs Market Size (2022 to 2027)

The size of the European Generic drugs market is estimated to value USD 105.34 billion by 2027 and USD 74.76 billion in 2022, growing at a CAGR of 7.10% during the forecast period.

Generic medicines are less expensive than brand-name pharmaceuticals, which has led to an increase in generic drug sales in the market. Because the cost of these medications is low, many companies have begun to invest in the production of generic drugs. The rising prevalence of chronic diseases, diabetes, cardiovascular diseases, the growing geriatric population, rising healthcare expenditure, high demand for generic medicines, and a large number of patent-expired branded drugs are all contributing to the growth of the European generic drugs market. Patients prefer generic drugs because generic drugs are less expensive and have the same chemical composition and potency. When a patient has a serious disease, the therapy lasts longer, resulting in a rise in generic medication sales.

The growing need for newer generic medications, the increased number of clinical studies, and the huge number of licensing and partnering strategies used by important vendors to introduce new products all contribute to considerable demand for European generic drugs in the near future. The rapid expansion of the pharmaceutical sector, as well as its growing percentage of overall healthcare spending, has reignited the age-old issue over how to balance the expense of innovation in drug development while also providing universal access to that research. 3D printing has the ability to change medication production in the generic medicines industry. 3D printed medications aid R&D productivity while also providing new benefits to patients. Drugs with customized size, form, and texture may be produced via 3D printing, which is not feasible with standard generic medication production. Because of the high frequency of chronic diseases, the government and many drug industries are boosting their R&D spending to develop new compounds and enhance current technology so that more patients' problems may be treated. As a result of all of these qualitative data, it is obvious that the generic medicine industry will grow considerably during the forecasted period.

Government restrictions and drug-related side effects are anticipated to hinder the European generic drugs market growth. One of the challenges in the generic medicines market in the European market is a lack of knowledge about generic medications. The heavy advertising and marketing of branded medications obscures the availability of generic drugs that can be used instead of the more expensive branded drugs.

This European Generic Drugs Market report has been segmented and sub-segmented into the following categories:

By Type: 

  • Pure Generic Drugs
  • Branded Generic Drugs

By Application: 

  • The Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The European generic drugs market is projected to expand as the frequency of chronic diseases rises in this region. For example, the number of people diagnosed with diabetes in Europe has increased in recent years, which is projected to raise demand for generic drugs. Many clinical trials have been delayed as a result of the pandemic, as researchers were not permitted to visit laboratories and continue those ongoing trials. If no disruption occurs, those molecules will enter the market as a patented molecule and will be taken away from the patient, resulting in an increase in the generic drug market in the forecasted periods. According to the World Health Organization, cervical cancer is one of the most prevalent diseases afflicting women in Europe, new cases diagnosed each year. As a result, throughout the projected period, a rising patient population is predicted to boost demand for generic drugs in Europe.

KEY MARKET PLAYERS:

A few of the notable companies dominating the European Generic Drugs Market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.

1.Introduction          

                1.1 Market Definition 

                1.2 Study Deliverables      

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions    

2. Research Methodology   

                2.1 Introduction       

                2.2 Research Phases   

    2.2.1 Secondary Research           

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling      

    2.2.4 Expert Validation  

                2.3 Analysis Design 

                2.4 Study Timeline  

3. Overview               

                3.1 Executive Summary    

                3.2 Key Inferences 

                3.3 Epidemology      

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            

                4.1 Market Drivers  

                4.2 Market Restraints 

                4.3 Key Challenges 

                4.4 Current Opportunities in the Market      

5. Market Segmentation      

                5.1 Type      

    5.1.1 Introduction           

    5.1.2 Biosimilars   

    5.1.3 simple generics     

    5.1.4 Super generics      

    5.1.5  Y-o-Y Growth Analysis, By Product  

    5.1.6  Market Attractiveness Analysis, By Product

    5.1.7  Market Share Analysis, By Product  

                5.2 Therapeutic drugs

    5.2.1 Introduction           

    5.2.2 Cardiovascular Products    

    5.2.3 Anti-infective Drugs

    5.2.4 Anti Arthritis Drugs  

    5.2.5 Central Nervous System Drugs       

    5.2.6 Anti Cancer Drugs

    5.2.7 Respiratory System Drugs

    5.2.8 Others      

    5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs          

    5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs      

    5.2.11 Market Share Analysis, By Therapeutic Drugs        

6. Geographical Analysis      

                6.1 Introduction       

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis        

6.1.3.1 By Geographical Area   

6.1.3.2 By Type     

6.1.3.3 By Therapeutic Drugs    

    6.1.4  Market Attractiveness Analysis     

6.1.4.1 By Geographical Area   

6.1.4.2 By Type     

6.1.4.3 By Therapeutic Drugs    

    6.1.5  Market Share Analysis      

6.1.5.1 By Geographical Area   

6.1.5.2 By type     

6.1.5.3 By Therapeutic Drugs    

                6.2 U.K     

                6.3 Spain     

                6.4 Germany  

                6.5 Italy       

                6.6 France  

7.Strategic Analysis

                7.1 PESTLE analysis 

    7.1.1 Political     

    7.1.2 Economic 

    7.1.3 Social         

    7.1.4 Technological         

    7.1.5 Legal          

    7.1.6 Environmental       

                7.2 Porter’s Five analysis      

    7.2.1 Bargaining Power of Suppliers        

    7.2.2 Bargaining Power of Consumers    

    7.2.3 Threat of New Entrants     

    7.2.4 Threat of Substitute Products and Services  

    7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis 

                8.1 Ranbaxy Laboratories    

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments       

    8.1.5 SWOT analysis       

    8.1.6 Analyst View          

                8.2 Actavis  

                8.3 Mylan, Inc. Industries, Ltd.      

                8.4 Dr. Reddy’s Laboratories   

                8.5 Par Pharmaceutical, Inc.

                8.6 Sandoz International GmbH    

                8.7 Celgene Corporation      

                8.8 Apotex, Inc.       

                8.9 Watson Pharmaceuticals, Ltd.    

                8.10 Teva Pharmaceutical and others. 

9.Competitive Landscape    

                9.1 Market share analysis    

                9.2 Merger and Acquisition Analysis    

                9.3 Agreements, collaborations and Joint Ventures 

                9.4 New Product Launches 

10.Market Outlook and Investment Opportunities  

Appendix   

                a) List of Tables    

                b) List of Figures      

  1. Europe Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  2. Europe Biosimilars Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Simple Generics Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Super Generics Market, By Region, From 2022 - 2027 (USD Billion)
  5. Europe Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)
  6. Europe Cardiovascular Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  7. Europe Anti-Infective Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  8. Europe Anti-Arthritic Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  9. Europe Central Nervous system Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe Anti-Cancer Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  11. Europe Respiratory Products Market, By Region, From 2022 - 2027 (USD Billion)
  12. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  13. U.K. Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  14. U.K. Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)
  15. Germany Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  16. Germany Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)
  17. France Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  18. France Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)
  19. Italy Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  20. Italy Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)
  21. Spain Generic Drugs Market, By Type, From 2022 - 2027 (USD Billion)
  22. Spain Generic Drugs Market, By Therapeutic Drugs, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample